trending Market Intelligence /marketintelligence/en/news-insights/trending/S8f1IiUHjzUzH1o2NMXc4w2 content
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

Vedanta Biosciences completes $27M series C financing

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry

Segment

IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help


Vedanta Biosciences completes $27M series C financing

Vedanta Biosciences Inc., a subsidiary of Boston-based PureTech Health PLC, completed a $27 million series C financing.

Vedanta Biosciences said it plans to use the proceeds to advance its pipeline of microbiome-derived product candidates, which include VE416, VE800 and VE303 for treating food allergy, advanced or metastatic cancers and a certain type of bacterial infection, respectively.

Invesco Asset Management Ltd., a shareholder of PureTech Health, and PureTech Health contributed $5 million each and subscribed to 220,751 preferred shares of Vedanta Biosciences.

Bill & Melinda Gates Foundation, Bristol-Myers Squibb Co., Rock Springs Capital Management LP and Seventure Partners SA also participated in the financing round.

Cambridge, Mass.-based Vedanta Biosciences develops treatments for human diseases based on research of the relationship between microbes and the human immune system.